Miller Howard Investments Inc. NY cut its stake in Medtronic plc (NYSE:MDT – Free Report) by 0.6% in the first quarter, HoldingsChannel reports. The fund owned 636,974 shares of the medical technology company’s stock after selling 3,601 shares during the period. Medtronic accounts for 1.8% of Miller Howard Investments Inc. NY’s holdings, making the stock its 21st largest position. Miller Howard Investments Inc. NY’s holdings in Medtronic were worth $55,512,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors also recently modified their holdings of the stock. Harbor Investment Advisory LLC lifted its position in Medtronic by 14.8% during the 1st quarter. Harbor Investment Advisory LLC now owns 15,913 shares of the medical technology company’s stock valued at $1,387,000 after purchasing an additional 2,051 shares during the period. Global Trust Asset Management LLC increased its stake in Medtronic by 81.0% in the first quarter. Global Trust Asset Management LLC now owns 3,148 shares of the medical technology company’s stock valued at $274,000 after purchasing an additional 1,409 shares in the last quarter. CHICAGO TRUST Co NA boosted its position in shares of Medtronic by 12.6% during the first quarter. CHICAGO TRUST Co NA now owns 10,087 shares of the medical technology company’s stock worth $879,000 after purchasing an additional 1,126 shares in the last quarter. First PREMIER Bank grew its holdings in shares of Medtronic by 31.0% in the 1st quarter. First PREMIER Bank now owns 6,330 shares of the medical technology company’s stock valued at $551,000 after buying an additional 1,499 shares during the period. Finally, Murphy Pohlad Asset Management LLC increased its position in shares of Medtronic by 2.8% in the 1st quarter. Murphy Pohlad Asset Management LLC now owns 78,675 shares of the medical technology company’s stock valued at $6,857,000 after buying an additional 2,170 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.
Insider Transactions at Medtronic
In other news, EVP Michael Marinaro sold 854 shares of the stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $83.14, for a total value of $71,001.56. Following the transaction, the executive vice president now directly owns 27,925 shares of the company’s stock, valued at $2,321,684.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Michael Marinaro sold 854 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $83.14, for a total transaction of $71,001.56. Following the completion of the sale, the executive vice president now owns 27,925 shares in the company, valued at $2,321,684.50. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Geoffrey Martha sold 19,113 shares of the stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $83.77, for a total value of $1,601,096.01. Following the transaction, the chief executive officer now owns 143,348 shares in the company, valued at approximately $12,008,261.96. The disclosure for this sale can be found here. 0.30% of the stock is currently owned by corporate insiders.
Medtronic Stock Down 0.7 %
Medtronic (NYSE:MDT – Get Free Report) last announced its quarterly earnings data on Thursday, May 23rd. The medical technology company reported $1.46 EPS for the quarter, beating analysts’ consensus estimates of $1.45 by $0.01. The company had revenue of $8.59 billion during the quarter, compared to the consensus estimate of $8.44 billion. Medtronic had a net margin of 11.36% and a return on equity of 13.47%. The company’s quarterly revenue was up .5% on a year-over-year basis. During the same quarter last year, the firm posted $1.57 EPS. On average, equities research analysts forecast that Medtronic plc will post 5.44 earnings per share for the current year.
Medtronic Increases Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 12th. Stockholders of record on Friday, June 28th will be given a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a dividend yield of 3.46%. This is a boost from Medtronic’s previous quarterly dividend of $0.69. The ex-dividend date is Friday, June 28th. Medtronic’s dividend payout ratio (DPR) is presently 100.36%.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently commented on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Medtronic in a research report on Friday, May 24th. Wells Fargo & Company increased their price objective on shares of Medtronic from $102.00 to $105.00 and gave the stock an “overweight” rating in a research report on Friday, May 24th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $92.00 price objective on shares of Medtronic in a research report on Wednesday, June 5th. Truist Financial dropped their price target on Medtronic from $90.00 to $88.00 and set a “hold” rating on the stock in a research note on Friday, May 24th. Finally, The Goldman Sachs Group started coverage on Medtronic in a research report on Thursday, May 30th. They set a “sell” rating and a $83.00 price objective for the company. Two analysts have rated the stock with a sell rating, five have issued a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $93.00.
Get Our Latest Stock Report on MDT
About Medtronic
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
Further Reading
- Five stocks we like better than Medtronic
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- The Top 3 Sectors Poised For Growth This Summer
- Why is the Ex-Dividend Date Significant to Investors?
- U.S. Steel Stock: Betting on EPS Cut and Merger Uncertainty?
- Best Stocks Under $5.00
- GitLab Stock: Pioneering the AI-Powered DevSecOps Platform
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic plc (NYSE:MDT – Free Report).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.